Form 4 for CALC CalciMedica, Inc.

Accepted 2023-05-03 00:00:00 ET · period of report 2023-03-20 · accession 0001209191-23-027196 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DMI	2023-05-03	2023-03-20	CALC	Valence Investments SPV V, LLC	10%	A - Grant	—	+382.3K	316.1K	New	—
D	2023-05-03	2023-03-20	CALC	Valence Investments SPV V, LLC	10%	A - Grant	—	+357.0K	357.0K	New	—
DMI	2023-05-03	2023-03-20	CALC	Valence Investments SPV V, LLC	10%	A - Grant	—	+19.9K	9,935	New	—

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-03-20	A	A	66,228	—	66,228	I By Valence Investments SPV VI, LLC	—	—	(F2) Received in exchange for 2,299,564 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
2	Common	Common Stock	2023-03-20	A	A	356,989	—	356,989	D By Valence Investments SPV V, LLC	—	—	(F1) Received in exchange for an aggregate of 12,395,423 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.
3	Common	Common Stock	2023-03-20	A	A	316,109	—	316,109	I	—	—	(F3) Received in exchange for 10,975,977 shares of the common stock of CalciMedica pursuant to the Merger Agreement.
4	Derivative	Warrant	2023-03-20	A	A	9,935	—	9,935	I By Valence Investments SPV V, LLC	$27.94 · — to 2026-02-22	9,935 Common Stock	(F5) Received in exchange for a warrant to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) Immediately exercisable.
5	Derivative	Warrant	2023-03-20	A	A	9,935	—	9,935	I By Valence Investments SPV V, LLC	$27.94 · — to 2026-06-25	9,935 Common Stock	(F5) Received in exchange for a warrant to acquire 344,934 shares of common stock of CalciMedica pursuant to the Merger Agreement. (F4) Immediately exercisable.